PTPN11 and juvenile myelomonocytic leukemia: Constitutive activation of the RAS/MAPK signaling pathway by mutations in KRAS and NRAS or their regulators PTPN11 (coding for SHP2), NF1, and CBL can be found in about 90% of JMML cases [3].